SuperworthFulcrum Therapeutics revenue FULC
Sales by quarter and over the last twelve months, from 2020.
- Last 12 months, to Dec 31, 2025
- n/m
- a quarter missing
- Latest quarter, Q4 FY25
- $0
- Fiscal year 2025
- n/a
Fulcrum Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q4 FY25, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | n/a | n/a |
| FY2024 | $80M | +2752% |
| FY2023 | $2.8M | −56% |
| FY2022 | $6.3M | −67% |
| FY2021 | $19.2M | +117% |
| FY2020 | $8.8M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY25 | $0 | n/a | n/a | |
| Q3 FY25 | $0 | n/a | n/a | |
| Q2 FY25 | $0 | −100% | n/a | |
| Q4 FY24 | $0 | −100% | $80M | |
| Q3 FY24 | $0 | −100% | $80.9M | |
| Q2 FY24 | $80M | +8991% | $81.6M | |
| Q1 FY24 | $0 | −100% | $2.5M | |
| Q4 FY23 | $871K | +27% | $2.8M | |
| Q3 FY23 | $759K | −36% | $2.6M | |
| Q2 FY23 | $880K | −53% | $3M | |
| Q1 FY23 | $295K | −89% | $4M | |
| Q4 FY22 | $685K | −86% | $6.3M |
Against its peers
Companies in Drug Manufacturers - General nearest Fulcrum Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| FULCFulcrum Therapeutics | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| ABUSArbutus Biopharma | $181.7M | |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| Peer median | $353M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Fulcrum Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.